Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases.

ABSTRACT: Background: This retrospective study compared the effectiveness and preliminary cost evaluation of denosumab and zoledronic acid (ZA) in patients with bone metastases from breast, prostate, and lung cancer. Methods: Patients treated with ZA or denosumab between January 2016 and August 2023 were analyzed. Outcomes included the incidence of skeletal-related events (SREs), time to first SRE, and cost per prevented SRE. An incremental cost-effectiveness analysis (ICER framework) was also performed, using prevention of SREs as the effectiveness outcome. Results: A total of 192 patients in the denosumab group and 239 in the ZA group were included. Denosumab significantly reduced the incidence of SREs compared with ZA (34.8% vs. 51.8%, p < 0.001). The median time to fi

SUBMITTER: Aliyev V 

PROVIDER: S-EPMC12470827 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature